The new strategy aims to transform ALK into a broader-based allergy company by building upon and accelerating our core allergy immunotherapy business – especially in North America, and expanding our presence into new adjacent business areas with complementary products and services, primarily by connecting with more people with allergy in the moments they need us the most.
Committed to helping many more people
CEO Carsten Hellmann says: ‘The world has changed for ALK compared to where we were two years ago. In that time, we have significantly grown our European business, we have invested heavily in North America and also in our legacy business. We believe that we can build further on these foundations to establish a bigger, more robust ALK, which is why we have decided, with support from our principal shareholder, to strengthen our financing to sustain the required high investment levels, predominantly in the USA.’
He continues: ‘We have successfully developed a new generation of SLIT-tablets and we believe that these products have the potential to make a major difference for people who suffer with severe allergies and related asthma. However, the fact is that the vast majority of people with allergies never receive AIT treatment while, for those who do, our products are typically a last resort after years of trying other solutions. In light of this, our goal is to build an effective future growth platform for these core products, and to leverage our profound expertise more effectively, engaging with patients earlier in their disease so that we can help many more people than we do today. It does not make sense to ignore 99% of the people suffering from allergies all around the world.’
The four pillars in the strategy
The new strategy has four key elements focusing on leveraging ALK’s unique expertise within allergy, our relationship with the allergy specialist community and our understanding of patients’ needs, to create growth and success for ALK.